By Anton Ladnyi, CFA · ex-Goldman Sachs · ex-J.P. MorganPublished Updated
ABBV — AbbVie at ~$209 on ~14x forward P/E (PEG 0.48) with Q1 2026 revenue +12.4% to $15B, Skyrizi $4.48B (+31%), Rinvoq $2.12B, Neuroscience +26%; FY2026 adj EPS guidance raised to $14.08-14.28 implying +45% growth; Skyrizi SC induction for Crohn's approved — the deepest-value large-cap pharma with clear multi-year earnings visibility.
ABBV Price Target & Rating
ABBV's quantitative grade is Strong Buy, with moderate downside risk (CVaR -10.3%), and quality metrics (net margin 6%). AbbVie Inc. (ABBV) trades at $224.95 with a valuation grade of Strong Buy: a trailing P/E of 109.7x at a 399% premium to sector median, net margins of 5.8%, a DCF-implied intrinsic range of $223–$415 suggesting a +42% margin of safety, beta 0.31 (defensive risk profile).
DCF Valuation Range
Key Takeaways
Valuation: Strong Buy grade — P/E 109.7x — DCF range $223–$415 implies +42% margin of safety
Risk: CVaR -10.3% (95th percentile, 1-month) indicates moderate tail exposure; beta of 0.31 amplifies broad market moves in both directions
Strengths: Size 4.5/5, 6% net margin dominate the factor profile
Catalyst: Skyrizi SC Crohn's market share data (Q3 2026 scripts); Rinvoq alopecia areata FDA decision; Neuroscience segment crossing $12B annualised run rate
Bear catalyst: Icotrokinra approved with superior profile to Skyrizi in Crohn's; Rinvoq safety concerns resurface; FCF guidance cut below $20B
Main riskP/E of 109.7x creates asymmetric downside on any earnings disappointment
Tail riskCVaR -10.3% over one month at the 95th percentile
DCF range$223–$415 intrinsic range; margin of safety +42%
Best useCore large-cap Healthcare holding — not a source of diversified sector exposure
Next watchEarnings surprise deceleration trend — monitor next quarter delivery closely
Quantitative Factor Profile
Value
2.0 / 5
Quality
3.0 / 5
Momentum
3.0 / 5
Volatility
5.0 / 5
Size
4.5 / 5
Key Metrics
ABBV Key Metrics — AbbVie Inc. 2026
Metric
Value
Current Price
$224.95
P/E Ratio (TTM)
109.7x
Forward P/E
13.8x
P/S Ratio
6.3
EV/EBITDA
15.4
Beta
0.31
Net Margin
5.8%
Dividend Yield
3.08%
CVaR (95%, 1M)
-10.3%
Market Cap
$397.4B
Analyst View
Anton Ladnyi, CFA · A.L. Capital AdvisoryUpdated 2026-06-11
Rating Rationale
ABBV — AbbVie at ~$209 on ~14x forward P/E (PEG 0.48) with Q1 2026 revenue +12.4% to $15B, Skyrizi $4.48B (+31%), Rinvoq $2.12B, Neuroscience +26%; FY2026 adj EPS guidance raised to $14.08-14.28 implying +45% growth; Skyrizi SC induction for Crohn's approved — the deepest-value large-cap pharma with clear multi-year earnings visibility.
Investment Thesis
↑ Bull Case
Skyrizi +30.9% to $4.48B in Q1; Rinvoq strong double-digit growth — combined tracking toward $31B+ in 2026, already 2 years ahead of AbbVie's own 2027 targets
Adj EPS growing ~45% in FY2026 at 14x forward P/E — one of the most extreme value/growth combinations in the S&P 500; PEG ratio ~0.48
Skyrizi SC (subcutaneous) induction for Crohn's: Phase 3 AFFIRM — 61% endoscopic response, 73% clinical remission — removes IV infusion requirement, expands addressable IBD market to primary care
~$24.6B FCF in 2026E at ~37% margin — among the highest absolute free cash flow generators in pharma; $100B US manufacturing 10-year commitment signals confidence
22 Buy/Strong Buy ratings, 0 Sells; consensus target $249 vs $209 current — broad institutional conviction
Multiple regulatory wins June 2026: FDA approved DECNUPAZ for BPDCN (rare blood cancer); EU approved AQUIPTA for acute migraine treatment; EU expanded VENCLYXTO label for untreated CLL; 21 presentations at EHA 2026 Congress (blood cancer portfolio)
Goldman Sachs 47th Annual Global Healthcare Conference June 9: management fireside chat; Piper Sandler raised PT to $298 Overweight; strong institutional buy consensus (22 Buy/0 Sell)
↓ Bear Case
Icotrokinra (oral IL-23 inhibitor): competing Crohn's/IBD drug in late-stage development; if approved and competitive with Skyrizi, could compress frontline IBD capture rate from 2027
Imbruvica -24.7% to $556M; BTK inhibitor market shifting away — another structural decline alongside Humira
Acquired IPR&D charges ($5B+ in 2025): non-cash but distort GAAP EPS dramatically ($2.65 adj vs $0.39 GAAP Q1 2026) — limits GAAP-based investor universe
Aesthetics (Botox Cosmetic, Juvederm) cyclically sensitive; China recovery uncertain; segment +7.6% is below group average
Morningstar downgraded to 2 stars June 1 ('newly overvalued') — 18% premium to fair value estimate; Humira revenue collapsed 38.6% to $688M (from $21B peak); patent headwinds ongoing
What Changes the Rating
↑Catalyst:Icotrokinra fails Phase 3 or shows inferior efficacy vs Skyrizi; Skyrizi SC captures >50% new IBD Rx starts; buyback accelerates above $5B/quarter
↓Stop / exit:Icotrokinra approved with superior profile to Skyrizi in Crohn's; Rinvoq safety concerns resurface; FCF guidance cut below $20B
Anton’s personal note
The model points to a strong buy and the DCF math backs it — there is real margin of safety here, which is rare at this stage of the cycle. The variable I track most closely is gross margin trajectory. That multiple can only be sustained if operating leverage is real — specifically whether the margin profile at scale supports what the market is already pricing in, or whether that future still needs to be earned. The setup that would make me more positive is a quarter that confirms the operating leverage story. The setup that would make me cautious is any signal that consensus estimates are getting ahead of fundamentals.
— Anton Ladnyi, CFA
Earnings History
ABBV Earnings History — EPS Surprise Rate 2026
Quarter
EPS Est.
EPS Actual
Surprise
Q1 2026
$2.67
$2.65
-0.8% ✗
Q4 2025
$2.65
$2.71
+2.2% ✓
Q3 2025
$1.78
$1.86
+4.2% ✓
Q2 2025
$2.91
$2.97
+2.1% ✓
Quarterly EPS — Estimate vs Actual
Earnings Projections
ABBV Forward EPS Consensus Estimates 2026
Quarter
EPS Est.
YoY EPS
Analysts
Q2 2026
$3.77
+26.9%
21
Q3 2026
$3.85
+106.8%
21
Q4 2026
~$3.99
+47.2%
31
Q1 2027
~$4.06
+53.2%
31
~ Estimated from annual consensus — not a direct analyst survey
Hover each scenario for detail · current price $224.95
▼
Bear Case
$162
-28.0%
Fwd P/E: 10.3x
6.0 revenue CAGR · 12.0 exit multiple
◆
Base Case
$248
+10.2%
Fwd P/E: 15.8x
12.0 revenue CAGR · 15.0 exit multiple
▲
Bull Case
$340
+51.1%
Fwd P/E: 21.7x
18.0 revenue CAGR · 19.0 exit multiple
Pairwise Correlation Matrix
0 of 10 peer pairs correlated above 0.60 — diversification benefit within this cluster is structurally limited.
Extended Analysis — Buy, Hold or Sell? Risk Factors. Portfolio Fit.
Is ABBV a buy, hold, or sell?
ABBV carries a valuation grade of Strong Buy. The trailing P/E of 109.7 sits 399% above the Healthcare sector median of 22.0x — a premium that demands sustained earnings delivery. Our discounted cash flow model produces an intrinsic range of $223–$415 — implying a +42% margin of safety at the current price of $224.95. The width of the DCF range reflects genuine uncertainty in the terminal growth rate assumption: the correct framework is a probability-weighted distribution over scenarios, not a single point estimate. See the DCF valuation framework for full methodology.
With a 9% beat rate on recent quarters, earnings predictability has been mixed. The most recent quarter missed by a 77.0% earnings surprise. Analyst estimate revisions are trending upward.
What are ABBV's key risk factors?
With a beta of 0.31, ABBV exhibits a low-volatility risk profile relative to the broad market. The 95th-percentile CVaR of -10.3% on a one-month horizon should inform position sizing directly: at a 10% portfolio weight, this tail event contributes approximately 1.0% of total portfolio loss in the worst 5% of months. Net margins of 5.8% fall below the Healthcare sector average of 18%, suggesting margin pressure.
Implied volatility of 1.9% is below realized volatility of 22.0%, potentially making options relatively cheap. Insiders have been net sellers to the tune of $104.4M recently. While routine dispositions are common, the magnitude bears watching. Short interest is low at 1.5% of float, suggesting limited bearish conviction.
How does ABBV fit in a diversified portfolio?
At typical HENRY portfolio weights — 10–20% of the equity allocation — ABBV carries a beta of 0.31, meaning it amplifies broad market moves proportionally. The appropriate weight is not a function of conviction alone, but of the full covariance structure across all holdings. See the Ledoit-Wolf covariance framework for the methodology behind these calculations.
Among closely correlated names, ABBV shows the strongest co-movement with PFE (0.42), JNJ (0.42), LLY (0.29). Investors seeking diversification should note these correlation dynamics when constructing multi-asset portfolios.
True portfolio risk is a function of the full covariance structure across all holdings — not individual stock metrics. The Portfolio Health Check quantifies this at the portfolio level: it surfaces hidden concentration, marginal CVaR contributions, and the degree to which your overall allocation deviates from an optimal risk-adjusted mandate. The ABBV analysis here is a single node in that larger structure.
For the portfolio construction framework underpinning ABBV’s position sizing and conviction rating — including IPS guardrails, Black-Litterman allocation, and CVaR constraints — see: Investment Policy Statement Framework →
Investor FAQ
Is ABBV a buy or sell in 2026?
AbbVie Inc. (ABBV) carries a Strong Buy quantitative rating from A.L. Capital Advisory, derived from Discounted Cash Flow intrinsic value analysis, five-factor model scoring (Value, Quality, Momentum, Volatility, Size), and CVaR tail risk measurement. At $224.95, the DCF midpoint margin of safety is +42% (intrinsic value range: $223 bear – $415 bull). Composite factor score: 3.5/5. Strongest factor: Volatility (5.0/5). Weakest factor: Value (2.0/5). Trailing P/E: 109.7x. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Portfolio Construction Framework →
What is the average analyst target price for ABBV?
Wall Street consensus target for ABBV: $253.55 (+12.7% upside from the current price of $224.95). The analyst target range spans $184.00 (most bearish) to $328.00 (most bullish). Consensus recommendation: Buy. Note that analyst price targets typically reflect a 12-month forward horizon and are derived from a blend of DCF, comparable-company, and sum-of-the-parts analysis. A.L. Capital Advisory’s quantitative Strong Buy rating is produced independently — from DCF intrinsic value, five-factor model scores, and CVaR tail risk — and does not mechanically track Street consensus. When the two diverge, the divergence itself is informative: it can reflect differences in time horizon, valuation methodology, or the degree to which the current price already discounts the consensus case. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Monte Carlo Simulation Framework →
How does ABBV score on Value, Quality, Momentum, Volatility, and Size?
ABBV five-factor scores (A.L. Capital Advisory, 1–5 scale): Value 2.0/5 (below average) — measures current price versus DCF intrinsic range and trailing earnings multiples; Quality 3.0/5 (neutral) — captures profitability metrics including return on equity, net margin and net margin (5.8%); Momentum 3.0/5 (neutral) — reflects recent price trajectory and earnings surprise consistency; Volatility 5.0/5 (strong) — inverse measure derived from beta, where lower historical volatility earns a higher score; Size 4.5/5 (strong) — market capitalisation rank (mega-cap $1T+ scores 5/5). Composite: 3.5/5. Factor scores above 4.0 signal a tailwind in that dimension; below 2.0 signals a material headwind. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Black-Litterman Model →
What is ABBV's tail risk and CVaR?
The 95th-percentile Conditional Value at Risk (CVaR) for ABBV on a one-month horizon is -10.3%. CVaR represents the expected average loss in the worst 5% of monthly outcomes — a more conservative tail risk measure than standard VaR, which only marks the loss threshold. Beta of 0.31 indicates below-market volatility. For reference, a diversified S&P 500 ETF carries a one-month CVaR of roughly -8% to -12% in normal market conditions; individual equity CVaR is higher due to idiosyncratic risk. At the portfolio level, what matters is the marginal CVaR contribution of each holding — not its standalone figure. The A.L. Capital Advisory Portfolio Health Check quantifies each position's marginal tail-risk contribution across your entire holdings. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: CVaR & Tail-Risk Methodology →
What is ABBV's intrinsic value and DCF price target?
A.L. Capital Advisory's DCF model produces an intrinsic value range of $223 (bear case) to $415 (bull case) for AbbVie Inc. (ABBV). At $224.95, the midpoint margin of safety is +42% (positive = discount to intrinsic mid; negative = premium). The bear-to-bull spread reflects genuine sensitivity to the two dominant DCF inputs: the terminal growth rate and WACC. Terminal value typically accounts for 60-80% of total intrinsic value in most equity DCF models, which is why a range is more analytically sound than a point estimate. The central analytical question is not what the DCF outputs as a single number but which growth trajectory the current market price already discounts. All DCF analysis follows CFA Institute standards and is conducted by Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: DCF Valuation Framework →
What would trigger a rating upgrade or downgrade for ABBV?
Upgrade trigger: Upgrade to Strong Buy on evidence of accelerating earnings surprise magnitude combined with improvement in the Value factor score — specifically if the current 109.7x P/E is supported by an upward revision to DCF terminal growth assumptions. Downgrade trigger: An earnings miss at current valuations (109.7x trailing P/E) where there is limited earnings cushion to absorb negative surprises; or a sustained reversal in the Quality and Momentum factor scores for two or more consecutive quarters. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Investment Policy Statement Framework →
Does ABBV consistently beat earnings estimates?
ABBV has beaten consensus EPS estimates in 9% of tracked quarterly periods — indicating inconsistent delivery. The most recent reported quarter missed consensus by 77.0%. Below-average earnings consistency is a primary headwind to the rating and a key watch item in the quantitative model. Earnings surprise magnitude and direction are incorporated into the Momentum and Quality dimensions of the five-factor scoring model. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: DCF Valuation Framework →
How does ABBV contribute to portfolio risk and diversification?
ABBV carries a beta of 0.31 (low-volatility / defensive relative to the broad equity market). A beta above 1.0 means the position amplifies market moves in both directions at a typical portfolio weight. Strongest peer co-movement: PFE (0.42), JNJ (0.42), LLY (0.29). Holding ABBV alongside these names in the same portfolio increases concentration risk. True portfolio risk is a function of the full covariance structure — a single stock's beta does not reveal its marginal contribution to portfolio tail loss. The A.L. Capital Advisory Portfolio Health Check quantifies concentration risk (Herfindahl-Hirschman Index), pairwise correlations, and marginal CVaR contribution across all your holdings. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: Ledoit-Wolf Covariance Framework →
What quantitative methodology does A.L. Capital Advisory use to analyse ABBV?
A.L. Capital Advisory analyses AbbVie Inc. (ABBV) using a four-component quantitative framework grounded in CFA Institute standards. (1) DCF Valuation: projects free cash flows under bear and bull assumptions, discounts at WACC to produce an intrinsic value range with margin-of-safety calculation. (2) Five-Factor Scoring: each equity is scored 1–5 on Value, Quality, Momentum, Volatility, and Size. (3) CVaR Tail Risk: 95th-percentile Conditional Value at Risk from historical simulation of daily returns on a one-month horizon. (4) Earnings Surprise Analysis: quarterly beat rate and magnitude are incorporated into the Momentum and Quality factor scores. The current Strong Buy rating for ABBV is the output of applying this complete framework to current data. Analysis by Anton Ladnyi, CFA (ex-Goldman Sachs, ex-J.P. Morgan) · A.L. Capital Advisory. Full methodology: DCF Valuation Framework → · CVaR & Tail-Risk Methodology →
Stress-Test This View Live
Run ABBV in Asset Lens
Live DCF valuation, Monte Carlo simulation, options flow intelligence, and full factor decomposition — updated in real time. Free, no account required.
This analysis is produced using a systematic quantitative framework applied to market data and does not constitute investment advice. Prose commentary is AI-assisted and generated from structured quantitative inputs. All data and metrics are as of 2026-06-11 and are point-in-time estimates subject to revision without notice. CVaR figures are based on historical simulation and do not guarantee future outcomes. DCF ranges and upgrade/downgrade triggers are forward-looking statements based on current assumptions and may not materialise. Past performance does not guarantee future results. This analysis does not account for individual circumstances, tax position, or investment objectives — consult a qualified financial advisor before making investment decisions. This content is intended for informational purposes only and does not constitute regulated investment advice under MiFID II or FCA guidelines. This content is not intended for US persons or residents of jurisdictions where its distribution would be contrary to local law or regulation. This service is not directed at residents of Finland, Sweden, Norway, Denmark, Iceland, or Poland. The author may hold long or short positions in securities mentioned in this analysis. Nothing on this page represents a solicitation to buy or sell any security. A.L. Capital Advisory is an independent private advisory practice and is not affiliated with AbbVie Inc.
CFA Portfolio Advisory — ABBV
Discuss this analysis, position sizing, or your full portfolio mandate with Anton Ladnyi, CFA.
